Drug:
Reaction: PRODUCT DOSE OMISSION ISSUE
20250101 - 20251231
No. 701 - 800
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 701 | 25112583 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 702 | 25112591 |
US |
2 | |
Ear infection, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 703 | 25112592 |
US |
1 | |
Drug ineffective, Product dose omission issue, Incorrect dose administered, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 704 | 25112593 |
US |
28 | 2 |
Pain, Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 705 | 25112596 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 706 | 25112601 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 707 | 25112604 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 708 | 25112636 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 709 | 25112642 |
US |
2 | |
Alopecia, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 710 | 25112643 |
US |
2 | |
Product dose omission issue, Insurance issue, Product distribution issue, Product quality issue, |
||||
BIMEKIZUMAB, |
||||
| 711 | 25112644 |
US |
1 | |
Psoriasis, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 712 | 25112645 |
US |
30 | 2 |
Product use issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 713 | 25112649 |
US |
2 | |
Product dose omission issue, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 714 | 25112650 |
US |
2 | |
Conjunctivitis, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 715 | 25112651 |
US |
1 | |
Psoriasis, Product dose omission issue, |
||||
BIMEKIZUMAB, SEMAGLUTIDE, INSULIN DEGLUDEC, ROSUVASTATIN CALCIUM, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, ESCITALOPRAM, |
||||
| 716 | 25112671 |
US |
2 | |
Pain, Candida infection, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 717 | 25112674 |
US |
2 | |
Viral infection, Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 718 | 25112675 |
US |
2 | |
Wrong technique in product usage process, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 719 | 25112677 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 720 | 25112684 |
US |
1 | |
Product dose omission issue, Device issue, |
||||
BIMEKIZUMAB, |
||||
| 721 | 25112687 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 722 | 25112688 |
US |
2 | |
Adverse drug reaction, Product dose omission issue, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 723 | 25112691 |
US |
64 | 2 |
Limb injury, Ankle fracture, Product dose omission issue, |
||||
TOFACITINIB, TOFACITINIB, |
||||
| 724 | 25112721 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, TIRZEPATIDE, |
||||
| 725 | 25112726 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 726 | 25112727 |
US |
2 | |
Respiratory tract infection, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 727 | 25112728 |
US |
2 | |
Diarrhoea, Bacterial infection, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 728 | 25112732 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 729 | 25112735 |
US |
2 | |
Psoriasis, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 730 | 25112737 |
US |
1 | |
Muscle spasms, Arthritis, Rhinorrhoea, Alopecia, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 731 | 25112747 |
US |
1 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 732 | 25112765 |
US |
||
Product dose omission issue, Device leakage, |
||||
BIMEKIZUMAB, |
||||
| 733 | 25112768 |
US |
2 | |
Injection site bruising, Injection site pain, Device issue, Incorrect dose administered, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 734 | 25112769 |
US |
2 | |
Product leakage, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 735 | 25112775 |
US |
2 | |
Pain, Rash, Skin irritation, Product dose omission issue, Drug ineffective, Loss of personal independence in daily activities, |
||||
BIMEKIZUMAB, FOLIC ACID, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LATANOPROST, BIMATOPROST, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 736 | 25112791 |
US |
2 | |
Product dose omission issue, Product use in unapproved indication, |
||||
PIMAVANSERIN TARTRATE, XANOMELINE AND TROSPIUM CHLORIDE, |
||||
| 737 | 25112801 |
US |
2 | |
Off label use, Product availability issue, Product dose omission issue, Therapy cessation, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 738 | 25112824 |
US |
2 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 739 | 25112830 |
US |
2 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 740 | 25112834 |
US |
72 | 2 |
Pruritus, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 741 | 25112835 |
US |
1 | |
Psoriasis, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 742 | 25112836 |
US |
2 | |
Headache, Diarrhoea, Psoriasis, Myalgia, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 743 | 25112840 |
US |
64 | 1 |
Influenza, Urinary tract infection, Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 744 | 25112907 |
US |
1 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 745 | 25112909 |
US |
2 | |
Pain, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 746 | 25112910 |
US |
2 | |
Illness, Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 747 | 25112913 |
US |
2 | |
Injection site pain, Nausea, Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 748 | 25112915 |
US |
2 | |
Injection site erythema, Injection site pruritus, Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, HYDROCORTISONE, |
||||
| 749 | 25112917 |
US |
1 | |
Inappropriate schedule of product administration, Device issue, Product dose omission issue, Product quality issue, |
||||
BIMEKIZUMAB, |
||||
| 750 | 25112922 |
US |
2 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 751 | 25112932 |
US |
24 | 1 |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 752 | 25112936 |
US |
2 | |
Psoriasis, Fatigue, Discomfort, Product dose omission issue, Insurance issue, |
||||
BIMEKIZUMAB, ZOLPIDEM TARTRATE, LEFLUNOMIDE, PREDNISONE, |
||||
| 753 | 25112956 |
US |
65 | 1 |
Product dose omission issue, Therapy interrupted, Inability to afford medication, |
||||
BIMEKIZUMAB, |
||||
| 754 | 25112962 |
US |
2 | |
Nonspecific reaction, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 755 | 25112969 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 756 | 25112975 |
US |
2 | |
Product administration error, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 757 | 25112984 |
US |
1 | |
Pruritus, Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 758 | 25112990 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 759 | 25113016 |
US |
1 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 760 | 25113028 |
US |
||
Anaphylactic reaction, Product dose omission issue, Asthma, Food allergy, Hypersensitivity, Manufacturing materials issue, |
||||
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 761 | 25113039 |
US |
2 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 762 | 25113042 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 763 | 25113050 |
US |
1 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 764 | 25113051 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 765 | 25113052 |
US |
2 | |
Helminthic infection, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 766 | 25113054 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 767 | 25113081 |
US |
2 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 768 | 25113091 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 769 | 25113093 |
US |
63 | 1 |
Product dose omission issue, Off label use, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 770 | 25113101 |
US |
2 | |
Folliculitis, Off label use, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 771 | 25113102 |
US |
2 | |
Product dose omission issue, Respiratory tract infection, |
||||
BIMEKIZUMAB, |
||||
| 772 | 25113103 |
US |
2 | |
Product dose omission issue, Intentional dose omission, |
||||
BIMEKIZUMAB, |
||||
| 773 | 25113108 |
US |
63 | 2 |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 774 | 25113110 |
US |
37 | 1 |
Product dose omission issue, Inability to afford medication, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 775 | 25113111 |
US |
1 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 776 | 25113152 |
US |
2 | |
Arthralgia, Product dose omission issue, |
||||
BIMEKIZUMAB, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, ESCITALOPRAM OXALATE, ESCITALOPRAM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ETODOLAC, |
||||
| 777 | 25113153 |
US |
61 | 1 |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 778 | 25113173 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 779 | 25113183 |
US |
20 | 2 |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 780 | 25113186 |
US |
46 | 1 |
Psoriasis, Candida infection, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, TAFASITAMAB-CXIX, |
||||
| 781 | 25113188 |
US |
2 | |
Psoriasis, Loss of personal independence in daily activities, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 782 | 25113191 |
US |
1 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 783 | 25113193 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 784 | 25113194 |
US |
2 | |
Psoriasis, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 785 | 25113195 |
US |
35 | 2 |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 786 | 25113210 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 787 | 25113219 |
GB |
2 | |
Illness, Product dose omission issue, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 788 | 25113240 |
US |
2 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 789 | 25113243 |
US |
31 | 2 |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 790 | 25113245 |
US |
46 | 2 |
Illness, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 791 | 25113281 |
US |
64 | 1 |
Product dose omission issue, Accidental exposure to product, Device malfunction, Incorrect dose administered, Device use error, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 792 | 25113284 |
US |
60 | 1 |
Psoriasis, Product dose omission issue, Device defective, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 793 | 25113288 |
US |
50 | 1 |
Product availability issue, Therapy interrupted, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 794 | 25113291 |
US |
2 | |
Injection site pain, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 795 | 25113294 |
US |
51 | 2 |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 796 | 25113296 |
US |
2 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 797 | 25113297 |
US |
2 | |
Tooth infection, Product availability issue, Product dose omission issue, Off label use, |
||||
BIMEKIZUMAB, |
||||
| 798 | 25113298 |
US |
1 | |
Injection site pain, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 799 | 25113310 |
US |
2 | |
Product dose omission issue, Device issue, Accidental exposure to product, |
||||
BIMEKIZUMAB, |
||||
| 800 | 25113312 |
US |
2 | |
Product dose omission issue, Device issue, |
||||
BIMEKIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28